We analyzed the relationship between the reinfusion of large or very large amounts of peripheral blood progenitor cells (PBPC) and hematologic toxicity in twentyone advanced breast cancer patients subjected to a myeloablative dose of melphalan at the end of a high-dose sequential chemotherapy (HDSC) program. We also evaluated the influence of the white blood cell (WBC) count to predict an optimal PBPC harvest after highdose chemotherapy and growth factor priming. Twentyone patients with high-risk or metastatic breast cancer sequentially received: high-dose cyclophosphamide (HD-Cy) and 
High-dose chemotherapy with autologous bone marrow transplantation for advanced breast cancer patients demonstrating high complete and overall response rates has previously been reported. 1, 2 PBPCs and growth factor have been used instead of bone marrow in recent trials resulting in a significant decrease in morbidity and mortality after myeloablative chemotherapy. 3 Nevertheless, little is known about the mechanism of mobilization, engraftment and immune reconstitutive capacity in an autologous PBPC transplantation setting. Currently, difficulties also arise in determining the appropriate timing and the extent of the PBPC collection as well as in defining the influence of various stem cell and progenitor cell doses on rapid and longterm engraftment. Moreover, improvements in PBPC transplantation strategies for solid tumors could depend on better patient selection as well as the advancement in PBPC technology. [3] [4] [5] Numerous phase II studies have suggested that the addition of hematopoietic growth factors to myelosuppressive chemotherapy strongly enhances PBPC mobilization, but optimal time to PBPC collection may vary from patient to patient, which makes the scheduling of leukapheresis logistically difficult. 3, 6, 7 In fact, no agreement exists regarding the optimal timing to start PBPC collection; furthermore, the PBPC threshold yield varies considerably in the trials. 3, [8] [9] [10] At present, 1 to 2 × 10 6 CD34 + cells per kilo-gram of body weight is considered as the minimum threshold below which rapid hematopoietic reconstitution may not occur and an increase in the PBPC dose is associated with a more rapid hematopoietic reconstitution. 10, 11 Although a correlation between infused CD34 + cells and neutrophil or platelet recovery has been reported, there seems to be an upper threshold above which an increase in the PBPC dose does not further hasten recovery. 9, 12 On the other hand, G-CSF and GM-CSF administration after PBPC infusion reduces time to neutrophil recovery, but it does not accelerate platelet engraftment. 9, 13 Therefore, there is no agreement on the optimal PBPC dose for minimizing the hematologic toxicity in the autotransplantation setting. Thus the problems related to hematologic toxicity (eg blood cell product support) limit the extensive use of high-dose chemotherapy strategies.
In 1993 we initiated a high-dose sequential chemotherapy program for high-risk primary and metastatic breast cancer patients, and our preliminary results were published. 14 Here, we report a retrospective analysis of the data regarding: (1) large PBPC collections following HD-Cy and G-CSF priming administered at the beginning of a sequence of non-cross-resistant drugs, and (2) the influence of large and very large amounts of PBPCs on hematologic toxicity following a myeloablative dose of melphalan administered as megatherapy at the end of this HDSC program.
Patients and methods

Patients' eligibility
We evaluated 21 women consecutively enrolled in a HDSC phase I/II pilot study. The eligibility criteria included: histo- II/III  -6  2  10  54  IV  -7.9  2  11  51  II/III  -4  4  12  49  II/III  -8.1  2  13  39  II/III  -8.2  2  14  48  IV (BMf)  CMF×6  8.3  2  15  48  II/III  -8.4  2  16  47  IV  CMF×6  6  3  17  31  IV (BMf)  CMF×6  9.3  2  18  36  II/III  -9.5  2  19  57  IV  Doxorubicin×1  11.2  3  20  60  IV (BMe)  CMF×6  12.2  2  21  37  II/III  -12.5  2 BMe or BMf = bone marrow extensive or focal involvement; F = 5-fluorouracil; C = cyclophosphamide; E = epidoxorubicin; Ta = Placitaxel.
Patients Nos 4 and 7 received local radiotherapy on bone lesions.
logically documented high-risk (more than four involved axillary nodes) and metastatic breast cancer including bone marrow involvement, WBC count Ͼ3 × 10 9 /l, platelet count Ͼ100 × 10 9 /l, Karnofsky performance status Ͼ80%, age no more than 60 years. Clinically significant cardiovascular disease, liver, pulmonary and renal impairment, and brain metastases were criteria for exclusion. All patients provided written informed consent in keeping with institutional ethical committee guidelines.
Treatment plan
Patients received HD-Cy (7 g/m 2 ) on day 1 followed by a sequential administration of HD-methotrexate (8 g/m ) on approximately day 60. G-CSF 5 g/kg/day administered subcutaneously (Filgrastim; Amgen Inc, Thousand Oaks, CA, USA) started 24 h after both cyclophosphamide and doxorubicin until complete hemopoietic reconstitution or completion of apheresis. No growth factor was administered after HD-L-PAM and PBPC reinfusion.
Procedures for PBPC collection, processing and reinfusion
PBPCs were mobilised in 21 patients by HD-Cy and G-CSF. Moreover, five patients completed their collection after HD-doxorubicin and G-CSF priming as they had failed the harvest after HD-Cy because of fever or technical problems. /kg CFU-GM. Collection was performed using an automatic continuous flow blood cell separator (Fenwall CS 3000; Baxter Healthcare, Gloucester, UK). Two blood volumes were processed during each apheretic procedure. Double access to the peripheral venous system was established by large cannulae or by a central venous catheter (CVC). Aliquots for CD34
+ cell analysis and clonogenic assay for CFU-GM were drawn from each individual leukapheresis product, both before cryopreservation and after thawing. Leukapheresis product was washed with a phosphate-buffered saline (PBS) and 4% human albumin. Freezing of the product was performed with 10% dimethylsulphoxide (DMSO) by noncontrolled rate freezing with storage at −80°C. The product was stored in cryobags in liquid nitrogen at a temperature of −196°C. Reinfusion of PBPCs was made after thawing in a 37°C waterbath and attaching the cryobag to intravenous tubing for infusion through a CVC.
Cytofluorimetric analysis of CD34
+ cells
Cytofluorimetric analysis was performed on white blood cell samples as previously described. 15 Briefly, peripheral blood circulating cells and cells harvested by apheresis were incubated with phycoerythrin-conjugated anti-CD34 monoclonal antibody (anti-HPCA-2; Becton Dickinson, Mountain View, CA, USA) for 30 min; red cells were then removed by treatment with a lysing buffer (Erythrolyse; Serotec, Oxford, UK) for 15 min. After extensive washing, peripheral blood leukocytes were analyzed by flow cytometry using a FACScan (Becton Dickinson). The number of circulating CD34
+ cells per microlitre of blood was obtained by multiplying the percentage of CD34
+ cells by the total number of circulating leukocytes in 1 microlitre of blood. The number of CD34 + cells harvested with each apheresis was obtained by multiplying the percentage of CD34 + cells by the total number of harvested nucleated cells.
Clonogenic assays
The procedure has already been described in detail by Tarella et al. 15 Briefly, myeloid progenitors (CFU-GM) were assayed in semisolid medium in the presence of: Iscove's modified Dulbecco's medium, agar 0.3%, FBS 20% and the supernatant of the 5637 cell line was used as stimulating factor. CFU-GM progenitor frequency was evaluated by plating blood samples from each apheresis before cryopreservation. To minimize errors, no enrichment steps were employed, and all tested samples were plated directly in the agar culture assay after appropriate dilutions.
Hematologic end-points
Hematologic toxicity was defined as the number of days with fewer than 1 × 10 9 /l leukocytes and 20 or 50 × 10 9 /l platelets after PBPC reinfusion. Engraftment was identified as the third day with more than 1 × 10 9 /l leukocytes and the first day with more than 20 × 10 9 /l platelets without transfusions following the HD-L-PAM induced nadir. The number of platelet transfusions was calculated by counting each single unit pooled product as one transfusion and the total number of red blood cell (RBC) transfused units was also recorded.
Statistical analysis
All results are presented as the median and range or mean and standard error except where otherwise stated. The Mann-Whitney unpaired U test was used for comparison of numerical data between treatment groups. Linear regression analysis was used to model the association between leukapheresis product CD34
+ cell and CFU-GM content, and between CD34
+ cells or CFU-CM or NC infused and the depth of the platelet nadir or time to hemopoietic reconstitution.
Results
Patient characteristics
Twenty-one consecutive breast cancer patients were enrolled in an HDSC study between November 1993 and May 1996. All patients were evaluated for the number of NC, CFU-GM, and CD34
+ cells during the mobilization, harvesting and transplantation time. The median age was 45 years (range 31-60). Seven patients had stage II/III high-risk disease (more than four axillary nodes involved), and 14 had metastatic disease. Five patients had histologically documented bone marrow metastasis; 12/14 metastatic patients were pre-treated with combination chemotherapy regimens for primary or advanced disease. Two patients had received previous local radiotherapy to bone lesions (Table 1) .
PBPC mobilization and harvest analysis
All patients underwent PBPC collection after HD-Cy mobilization and five of them completed their PBPC harvest after HD-doxorubicin priming. Each patient underwent a median of 3 (range 2-4) consecutive procedures ( Table 1) . The median PBPC yield from each collection was 6 × 10 + circulating cell number and the CD34 + cell yield (r = 0.7), as well as between the collected CD34 + cells and CFU-GM (r = 0.88) (Figures 1a and b) . In Figure 2 we report the different PBPC yields from leukaphereses carried out with different WBC counts. In particular, 29 collections performed with WBC counts ranging between 5 and 20 × 10 CFU-GM, 553 Ϯ 64 × 10 6 CD34 + cells, 12.6 Ϯ 0.9 × 10 9 NC. As reported in Table 2 , there was a statistically significant advantage for the PBPC harvests carried out with a WBC count higher than 20 × 10 9 /l (CFU-GM, P = 0.004; CD34 + cells, P = 0.004). The data regarding 11 collections carried out after HD-doxorubicin seem to reproduce the results of the HD-CY mobilization and harvesting, but they were not sufficient for statistical analysis (data not shown).
Hematologic recovery and toxicity after high-dose melphalan and PBPC transplantation
All patients admitted to the study completed the HDSC program and underwent HD-L-PAM (200 mg/m 2 ) and PBPC rescue. No growth factor was administered after the PBPC reinfusion. As shown in Table 3 3-7. 3). The aplasia started on day +7 (range +5 to +9) after HD-L-PAM, and the WBC nadir ranged between 0.1 and 0.4 × 10 9 /l. There were 6 days (range 4-9) with leukocytopenia, and time to more than 1 × 10 9 /l leukocytes for 3 consecutive days was day +13 (range [11] [12] [13] [14] [15] [16] . Median number of days with less than 20 or less than 50 × 10 9 /l platelets was 0 (range 0-3) and 3 days (range 0-7), respectively, while median time to reach more than 100 × 10 9 /l platelets was 12.5 days (range [11] [12] [13] [14] [15] [16] [17] . The median platelet count nadir was 22 × 10 9 /l (range 9-50 × 10 9 /l). Only nine out of 21 patients required platelet support, while all patients but two needed 2 RBC unit transfusions (range 0-5). All patients experienced gastrointestinal toxicity (nausea and vomiting) and mucositis (degree I/III WHO) that persisted for 9 days (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Eleven patients needed opioid analgesic drugs. Median time with fever higher than 38°C was 9 days (range 0-23) and all patients needed antibiotics and/or antifungals and/or antiviral drugs for a median time of 10 days (range 5-17). The total hospitalization after PBPC reinfusion was 20 days (range 15-30). Data on hematologic or non-hematologic toxicity and blood product support are listed in Table 3 .
Relationship between different PBPC doses and hematologic toxicity
On linear regression analysis the number of infused CD34 + cells correlated with both the platelet nadir ( Figure 3 ) and the time to 50 × 10 9 /l platelets (r = 0.73 and r = 0.7, respectively), but it did not significantly correlate with the duration of severe leukocytopenia (r = 0.2). The number of infused CFU-GM showed a small correlation with the platelet nadir or the time to 50 × 10 9 /l platelets (r = 0.36; r = 0.48), and no correlation was observed with the duration of severe leukocytopenia (data not shown). As reported in Table 4 , 12 patients in whom very large amounts of CD34 + group experienced a significantly shorter time with fewer than 50 × 10 9 /l platelets (1.5 vs 5 days respectively, P = 0.0036), a shorter median time with severe leukocytopenia (5 vs 6 days respectively, P = 0.3), a smaller RBC support (1.5 vs 3 RBC unit, P = 0.063) and mucositis requiring analgesia was experienced in five vs six patients and for a shorter time (8 vs 11 days). No difference was found in the number of days with fever, antibiotic administrations or total hospital support (data not shown).
Discussion
The use of PBPCs during myeloablative or deeply myelosuppressive treatments has become a standard procedure because it guarantees a rapid hemopoietic reconstitution. 3, 16 However, a period of severe thrombocytopenia and neutropenia persists, limiting the use of this chemotherapeutic strategy. We carried out a HDSC study for the treatment of advanced breast cancer patients, and we used large and 
and G-CSF. The mean number of nucleated cells (NC), CD34
+ cells and CFU-GM refer to the collections carried out with different WBC counts: nine collections performed with WBC count ranging between 5000 and 10 000/l; 20 collections performed with WBC count ranging between 10 000 and 20 000/l; 10 collections performed with WBC count ranging between 20 000 and 35 000/l; five collections performed with WBC count ranging between 35 and 55 000/l. ‫ء‬The CD34 + circulating cell number recorded during different WBC counts is also reported.
Table 2
Influence of WBC count on PBPCs yield after HD-cyclophosphamide and G-CSF mobilization very large amounts of PBPCs as rescue after megatherapy with high-dose melphalan to obtain a rapid hemopoietic reconstitution, and to limit hematologic toxicity to the greatest possible degree. Our data demonstrated that: (1) a dose-response relationship exists between the infused dose of PBPCs and platelet engraftment; (2) an optimal CD34 + cell threshold results in the removal of both severe thrombocytopenia and platelet support; (3) it is possible to obtain a very high number of PBPCs by priming with HD-Cy and G-CSF if the collections coincide with a WBC count higher than 20 × 10 9 /l. Several studies have analyzed the variables which could influence the PBPC harvest and hemopoietic reconstitution aiming at reducing the toxicity and the cost of high-dose chemotherapy. In particular, myelosuppression, time to collection, number of aphereses, PBPC dose, and the megatherapy schedule have been demonstrated to be the most important factors in this setting. 5, 17 We chose cyclophosphamide at a myelosuppressive dose as the first ingredient of the HDSC program because this drug is active against breast cancer cells and it also allows a high PBPC harvest after a previous theoretical 'in vivo' bone marrow purging. 18 We observed that the late collections, carried out when the WBC count was higher than 20 × 10 9 /l, yielded twice as many CD34
+ cells and CFU-GM compared to earlier collections carried out with a smaller WBC count. This phenomenon seems to be due to the parallel increase of leukocytes and CD34
+ circulating cells (Figure 1a and Figure 2) primed by a myelosuppressive treatment as HD-Cy. On the other hand, similar results seem possible with nonmyelosuppressive treatment, but our data, obtained from 11 collections carried out after HD-doxorubicin, are not sufficient to confirm that. In early studies, the collection of PBPCs began as soon as the WBC count rose to 1 × 10 9 /l, while at least 2.5 or 10 × 10 9 /l leukocytes was the threshold for the beginning of apheresis in more recent trials. 5, 8, 10 Moreover, Pettengel et al 19 identified the optimal time for PBPC collection as the moment at which the WBC count is increasing exponentially after chemotherapy-induced nadir, because at this time the rising leukocyte count parallels the 976 Hematologic toxicity days with Ͻ1 × 10 9 /l WBC 6 (4-9) days with Ͻ20 × 10 release of primitive hemopoietic cells. In addition, after priming by G-CSF alone, leukapheresis coincides with a WBC count higher than 20 × 10 9 /l. 20 There is some concern about the strategy for collecting PBPCs during the late phases of mobilization. This is because later collection can theoretically result in a yield predominantly of more committed progenitor cells at some sacrifice to long-term repopulating stem cells, thus becoming a potential risk for longterm engraftment. In spite of this, reassuring data have been reported by Bender et al, 21 and by our previous study that demonstrated a positive correlation between both committed progenitor cells (CFU-GM) and long-term repopulating stem cells (LTC-IC) during mobilization. 15 Furthermore, during the late phase of mobilization a higher number of nucleated cells are collected with a greater risk of tumor cell contamination. In our experience, however, patients transplanted with a higher number of CD34 + cells did not receive a higher dose of nucleated cells (Table 4) . Finally, there are conflicting data regarding tumor cell contamination in PBPC collections. In particular, no more tumor cells circulate after G-CSF or chemotherapy plus GM-CSF priming, and tumor cells contaminating PBPC collections are not clonogenic, thus they do not seem to be associated with the probability of early relapse or progression after transplantation. [22] [23] [24] Our patients underwent two to four leukaphereses, and this likely resulted in some discomfort for the patients, as well as higher costs. In fact, some recent studies have reported a sufficient PBPC yield with just a single collection. 7 However, it seems reasonable and costeffective to carry out more than a single apheresis to collect very large amounts of PBPCs in order to eliminate platelet transfusion requirements and to minimize RBC support. Recently, the importance of the PBPC dose and the relationship between the CD34 + cell dose and the hematologic toxicity control has been described. 25 In particular, Weaver et al 9 analyzing data on 692 patients demonstrated that different levels of infused CD34 + cells (Ͻ5; 5-10; Ͼ10 × 10 To date, the possibility of eliminating severe thrombocytopenia or platelet support after myeloablative chemotherapy and PBPC transplantation has not been reported, but rarely have more than 15 × 10 6 /kg CD34 + cells been used. Siena et al 11 in a small number of patients transplanted more than 20 × 10 6 /kg CD34 + cells after a myeloablative treatment obtaining an extraordinarily rapid and complete hematopoietic recovery. Recently, analyzing data on a large number of PBPC transplantations, Ketterer et al 26 suggested that the reinfusion of greater than 15 × 10 6 /kg CD34 + cells shortens hematopoietic reconstitution, reducing the platelet requirement to a minimum. We transplanted an optimal number of PBPCs into 21 breast cancer patients, and observed a significant dose-response relationship between the CD34 + cell dose and the level of the nadir platelet count, while there was no significant relationship with the duration of leukocytopenia. In particular, time to neutrophil engraftment was short, and was consistent with the data reported by Ayash et al, 27 who used the same megatherapy. Conversely, time to platelet recovery was very short, and all patients reached more than 100 × 10 9 /l platelets after 11-17 days following PBPC reinfusion. However, only the group of patients that received . We used HD-L-PAM at the end of an HDSC schedule because it is effective in advanced breast cancer, and its short half-life allows PBPC reinfusion after only 24 h. Until now, the studies which used HD-L-PAM showed both a stronger hematologic toxicity and a slower time to recovery in comparison to our experience. Our results demonstrate that by varying the CD34 + cell dose it is possible to modulate the hematologic toxicity and to eliminate severe thrombocytopenia and platelet transfusion requirements. A number of explanations support our data. First, the short interval between HD-L-PAM administration and PBPC reinfusion can permit a faster homing of more committed CD34 + cells, thus abating the cytotoxic effects of this drug. In a recent paper Somlo et al 30 theorized that a small 'sacrificial' dose of PBPCs could be reinfused concomitantly with HD-chemotherapy, producing a further acceleration of early hematopoietic recovery. Second, the reinfusion of large amounts of CD34 + cells with advanced megakaryocytic (MK) commitment can quickly produce a significant number of platelets. In fact, cells of the megakaryocyte lineage, are remarkably overrepresented in the CD34 + precursors, and MK progenitors (BFU-meg and CFU-Meg) slightly increase during the mobilization time. 31, 32 Recently, Bertolini et al 33 have generated megakaryocytes during 10-12 days of ex vivo culture from mobilised CD34 + cells. Two out of 10 patients who received the highest doses of cultured MK progenitors, did not require platelet transfusion support in this study. 33 In our study, large amounts of CD34 + cells were collected at the late phase of mobilization. It is hypothetical that a large number of very committed megakaryocytic progenitors are harvested during this period, and these cells could mature just a short time after reinfusion. Finally, we could have favored platelet engraftment because we did not use myeloid growth factors after transplantation. In fact, one study reported that G-CSF administration after PBPC transplantation can hamper platelet recovery. 34 Our data refer to a limited number of patients, and it would be useful to confirm our results in a larger prospective trial. However, these results strongly indicate that in an autologous transplantation setting it does not seems reasonable to establish a maximum threshold over which a further number of infused CD34 + cells is useless, because very large amounts of PBPCs can eliminate severe thrombocytopenia (at least when there is a short interval between megatherapy and PBPCs infusion) and can reduce RBC transfusion requests. Thus a short time with neutropenia, minimal or no exposure to blood products, lower risk of HLA alloimmunization, lower hospital costs and fewer outpatients for platelet transfusions are important benefits which can be achieved with very large amounts of PBPCs. These are all important factors, considering that the demand for platelet transfusion support has almost tripled in the past 12 years, 35 and that the tendency of recent trials is to foresee more myeloablative treatments followed by multiple PBPCs reinfusions and also to transfer high-dose chemotherapy to an outpatient setting. 
